{
    "clinical_study": {
        "@rank": "4813", 
        "brief_summary": {
            "textblock": "An open-label, clinical trial of autologous cMet redirected T cells administered\n      intratumorally (IT) in patients with breast cancer.  Fifteen evaluable patients will be\n      enrolled in stepwise fashion.  Step 1 will enroll patients with metastatic breast cancer\n      refractory to at least 1 standard therapy, step 2 will include newly diagnosed patients with\n      operable triple negative breast cancer."
        }, 
        "brief_title": "eMet CAR RNA T Cells Targeting Breast Cancer", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Metastatic Breast Cancer", 
            "Triple Negative Breast Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "This study is designed to determine the safety and feasibility of intratumoral\n      administration of autologous T cells that have had genetic material transferred into the\n      cell to redirect them to target breast cancer cells rather than their usual target.\n      Eligible subjects will have metastatic breast cancer refractory to at least one standard\n      therapy or to newly diagnosed with operable triple negative breast cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Step 1 subjects only: metastatic breast patients refractory to at least one standard\n             therapy, with easily accessible metastatic deposits (cutaneous, subcutaneous, or\n             superficial and/or palpable adenopathy/mass).\n\n          -  Step 2 subjects only: Newly diagnosed, operable, triple negative breast cancer, i.e.\n             ER/PRnegative, her2/neu-negative, with tumor size between between 2- 5 cm (T2) as\n             measured by either clinical breast exam, mammogram, ultrasound or MRI, with or\n             without ipsilateral axilla node involvement (N0 or N1).\n\n          -  cMet expression in greater than or equal to 30% tumor cells as demonstrated on\n             immuno-histochemistry analysis of archival slides. Punch biopsy or percutaneous core\n             biopsy may be offered to Cohort 1 patients.\n\n          -  Age greater than or equal to 18 years old\n\n          -  Baseline Eastern Cooperative Oncology Group (ECOG) Clinical Performance Status 0 or 1\n\n          -  Life expectancy greater than 6 months\n\n          -  Adequate hematologic function established within 14 days before treatment:\n\n          -  WBC greater than or equal to 3.0\n\n          -  Plt greater than or equal to 75,000\n\n          -  Hgb greater than or equal to 10 g/dl\n\n          -  dequate renal function established within 14 days before treatment defined as serum\n             creatinine less than 1.5 times upper limit of normal\n\n          -  Adequate hepatic function established within 14 days before treatment defined as:\n\n          -  Total bilirubin less than 1.5 times upper limit of normal, and\n\n          -  ALT and AST less than 2.5 times upper limit of normal\n\n          -  Women of child bearing potential must have a negative pregnancy test (blood or urine)\n             within 14 days before treatment and agree to use appropriate contraception from study\n             screen through the duration of the trial. Men must agree to use appropriate\n             contraception from study screen through the duration of the trial.\n\n          -  Tumor staging by standard imaging within the past 30 days (Step 1 subjects only).\n\n          -  Signed and dated written informed consent.\n\n        Exclusion Criteria:\n\n          -  Step 1 subjects only:\n\n          -  Currently taking cytotoxic chemotherapy; however, patients receiving\n             non-investigational hormone therapy, lapatinib, and/or trastuzumab are eligible\n             provided these medicines are at a stable dose and were begun more than 30 days prior\n             to the first IT injection\n\n          -  Metastatic deposits near a great vessel or spinal cord\n\n          -  Step 2 subjects only:\n\n          -  Prior therapy for breast cancer\n\n          -  Women already undergoing neoadjuvant chemotherapy to treat their primary triple\n             negative breast cancer\n\n          -  Step 1 and 2 subjects:\n\n          -  Positivity for HIV-1/HIV-2, Hepatitis B virus, and Hepatitis C virus active infection\n\n          -  The use of the following within 30 days before treatment:\n\n          -  Immunosuppressive drugs\n\n          -  Systemic glucocorticoids\n\n          -  Hematopoietic growth factors\n\n          -  Experimental therapy\n\n          -  Use of anti-coagulants such as coumadin, heparin, or Lovenox within 14 days before\n             treatment\n\n          -  Pregnant women or nursing mothers\n\n          -  History of alcohol abuse or illicit drug use within 12 months of study initiation\n\n          -  Clinically significant comorbid disease or other underlying condition, including\n             major autoimmune disorders that would contraindicate study therapy or confuse\n             interpretation of study results\n\n          -  Significant psychiatric disorder and any other reason in the Investigators opinion\n             that would jeopardize protocol compliance or compromise the patients ability to give\n             informed consent.\n\n          -  Prior MI ascertained from medical history and review of systems"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 18, 2013", 
        "id_info": {
            "nct_id": "NCT01837602", 
            "org_study_id": "UPCC 13111"
        }, 
        "intervention": {
            "intervention_name": "cMet RNA CAR T cells", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "refractory to at least one standard therapy", 
            "newly diagnosed", 
            "with operable triple negative breast cancer"
        ], 
        "lastchanged_date": "February 28, 2014", 
        "location": {
            "contact": {
                "email": "PennCancerTrials@emergingmed.com", 
                "last_name": "Julia Tchou, MD", 
                "phone": "855-216-0098"
            }, 
            "facility": {
                "address": {
                    "city": "Philadelphia", 
                    "country": "United States", 
                    "state": "Pennsylvania", 
                    "zip": "19104"
                }, 
                "name": "Abramson Cancer Center of the University of Pennsylvania"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Clinical Trial of Autologous cMet Redirected T Cells Administered Intratumorally in Patients With Breast Cancer", 
        "overall_contact": {
            "email": "PennCancerTrials@emergingmed.com", 
            "last_name": "Juliia Tchou, MD", 
            "phone": "855-216-0098"
        }, 
        "overall_official": {
            "affiliation": "Abramson Cancer Center of the University of Pennsylvania", 
            "last_name": "Julia Tchou, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Serious Adverse Event", 
            "safety_issue": "Yes", 
            "time_frame": "Two years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01837602"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Abramson Cancer Center of the University of Pennsylvania", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Abramson Cancer Center of the University of Pennsylvania", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}